Clinical Trial

Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with relapsed/refractory autoimmune inflammatory diseases (AID).
Trial Details
NCT Number NCT06970951
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies, Systemic Sclerosis
Enrollment 15 participants
Start Date 2025-05-18
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-14